DMRA Stock Rises on DMR-001 mutCALR Blood Cancer Pipeline: Is Damora Therapeutics a New MPN Biotech Play?
Key Takeaways Damora Therapeutics (NASDAQ: DMRA) rose as investors focused on the company’s DMR-001 program, a potential targeted therapy for mutant calreticulin-driven blood cancers. DMRA stock is not moving because of commercial revenue or earnings. The company remains a clinical-development biotech story. The main catalyst is DMR-001, an anti-mutCALR antibody designed for patients with mutant … Read more